Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company based in South San Francisco, is gaining attention for its development of innovative therapeutic products for the acute treatment of migraines. With its lead product, STS101, the company is currently in the midst of SUMMIT Phase 3 efficacy trials. This drug-device combo is comprised of a proprietary dry-powder formulation of dihydroergotamine mesylate that can be self-administered with Satsuma's unique pre-filled, single-use, and nasal delivery device. Since its inception in 2016, Satsuma Pharmaceuticals, Inc. has been at the forefront of biopharmaceutical advancements and is set to be a game changer in the field of migraine treatment.